Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apogee Therapeutics, Inc. (APGE) SEC filings page on Stock Titan aggregates the company’s U.S. Securities and Exchange Commission disclosures, providing insight into its status as a Nasdaq-listed, clinical-stage biotechnology issuer. These documents include current reports on Form 8-K, financial statements, equity offering details and other regulatory information that frame Apogee’s development and financing activities in inflammatory and immunology (I&I) therapeutics.
Apogee’s Forms 8-K illustrate how the company reports material events such as quarterly financial results, interim clinical data for programs like APG777 and APG333, and the terms of underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement. Selected 8-Ks also summarize outcomes of the annual meeting of stockholders, including director elections, auditor ratification and advisory votes on executive compensation frequency.
Through these filings, investors can review Apogee’s reported research and development and general and administrative expenses, net losses, cash and marketable securities balances, and the impact of capital raises on its operating runway. Offering-related filings describe underwriting agreements, option exercises by underwriters, pre-funded warrant terms and associated legal opinions, all of which help clarify the structure of Apogee’s capital formation.
On Stock Titan, users can access Apogee’s SEC filings alongside AI-powered summaries that explain the key points of lengthy documents such as earnings-related 8-Ks and registration statement updates. This includes highlighting where the company discusses clinical trial timelines, interim data disclosures, and other items relevant to its I&I pipeline. The filings page also surfaces exhibits like press releases and data presentations incorporated into 8-Ks, as well as cover page information confirming that Apogee’s common stock trades on The Nasdaq Global Market under the symbol APGE.
For those monitoring regulatory developments, capital structure changes or disclosure around programs such as APG777, APG279 and APG333, the SEC filings page offers an organized view of Apogee’s official communications with regulators and investors.
Andrew Gottesdiener, Director at Apogee Therapeutics, received a stock option grant to purchase 14,461 shares of common stock at an exercise price of $41.66 per share on June 17, 2025.
Key details of the option grant:
- Exercise price: $41.66 per share
- Vesting: 100% on one-year anniversary of grant date
- Expiration date: June 17, 2035
- Subject to continued service with the company
Notable arrangement: The options are held under an agreement with VR Management, LLC, where Gottesdiener must exercise the options solely at their direction. VR Management is entitled to the underlying shares, with Gottesdiener disclaiming beneficial ownership except for his pecuniary interest.
Apogee Therapeutics director Jennifer A. Fox received a stock option grant on June 17, 2025. The derivative security details include:
- Right to purchase 14,461 shares of common stock
- Exercise price set at $41.66 per share
- Options will vest in full on the one-year anniversary of the grant date (June 17, 2026)
- Expiration date is June 17, 2035
- Total grant value at $0.00 cost to the director
The vesting is contingent upon Fox's continued service with Apogee Therapeutics. The Form 4 was filed through an attorney-in-fact, Matthew Batters, on June 20, 2025. This equity compensation grant aligns with standard director compensation practices and creates long-term alignment with shareholder interests.
Form 4 Filing Details: Lisa Bollinger, Director at Apogee Therapeutics (NASDAQ: APGE), received a stock option grant on June 17, 2025. The derivative securities transaction involves the right to purchase 14,461 shares of common stock at an exercise price of $41.66 per share.
The stock option grant has the following key terms:
- Exercise price: $41.66 per share
- Expiration date: June 17, 2035
- Vesting schedule: 100% vesting on the one-year anniversary of the grant date
- Vesting condition: Subject to continued service with the company
The filing was signed by Matthew Batters as attorney-in-fact for Lisa Bollinger on June 20, 2025. This represents a standard equity compensation grant for a board member, structured as a ten-year option with cliff vesting.
On 17 June 2025 Apogee Therapeutics, Inc. (Nasdaq: APGE) held its 2025 Annual Meeting of Stockholders. Shareholders elected three Class II directors—Dr Lisa Bollinger (35.1 M votes for), Tomas Kiselak (39.2 M) and Nimish Shah (25.8 M)—to serve until the 2028 meeting; abstentions ranged from 0.2 M to 13.6 M and 1.8 M broker non-votes were recorded for each nominee.
Ernst & Young LLP was ratified as independent auditor for fiscal 2025 with 41.16 M votes in favor (99.9%), 3,099 against and 26,229 abstentions.
In the non-binding vote on the frequency of future “say-on-pay” proposals, a decisive 39.35 M shares (≈99%) supported annual advisory votes; the Board will adopt this cadence going forward.
No financial results, strategic transactions or other material events were disclosed. The filing is routine corporate-governance housekeeping and is unlikely to affect the company’s valuation or near-term outlook.